Embolisation has become an accepted modality of cancer treatment in patients with a variety of clinical scenarios. It is commonly used in clinical practice in the treatment of hepatocellular carcinoma, hepatic metastases from colorectal cancer and neuroendocrine tumours, and renal cell carcinoma. This review summarizes the current evidence for the efficacy of embolotherapy in these clinical settings, together with the associated complications.

Author

J A Goode and M B Matson

Contact Details

Corresponding address:
The Royal London Hospital,
Barts and The London NHS Trust,
Whitechapel Road.
London, E1 1BB,
UK

Reference

ICIS Cancer Imaging volume 4
DOI: 10.1102/1470-7330.2004.0021

Date Posted

17 September 2004

Print PDF

Size

3.46 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	13 seconds
ADSL 512Kb/s (Broadband):	55 seconds
64 Kb/s (ISDN):	7 minutes 23 seconds
33.3 Kb/s (Typical Modem):	14 minutes 11 seconds

Screen PDF

Size

376.60 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	5 seconds
64 Kb/s (ISDN):	47 seconds
33.3 Kb/s (Typical Modem):	1 minute 30 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.